Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda | pembrolizumab | Esophageal carcinoma, gastroesophageal junction adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Myinfla | colchicine | Atherothrombotic events in coronary artery disease | Do not reimburse | Complete | ||
| Ngenla | somatrogon | Growth hormone deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Emgality | galcanezumab | Prevention of migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Increlex | mecasermin | Severe primary insulin-like growth factor-1 deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | ||
| Padcev | enfortumab vedotin | Locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
| HyQvia | immune globulin human and recombinant human hyaluronidase | Humoral immunodeficiency | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 28, 2024